中华普通外科学文献（电子版）
中華普通外科學文獻（電子版）
중화보통외과학문헌（전자판）
CHINESE JOURNAL OF GENERAL SURGERY(ELECTRONIC VERSION)
2013年
4期
298-302
,共5页
戴强生%李鹤平%龙健婷%曾睿芳%张冰%周波%幸思忠%曾志荣%陈伟%杨建勇
戴彊生%李鶴平%龍健婷%曾睿芳%張冰%週波%倖思忠%曾誌榮%陳偉%楊建勇
대강생%리학평%룡건정%증예방%장빙%주파%행사충%증지영%진위%양건용
树突状细胞%HBs-Ag基因%HepG2 22.1.5肝癌细胞%瘤苗%基因疗法%β-葡萄糖神经酰胺
樹突狀細胞%HBs-Ag基因%HepG2 22.1.5肝癌細胞%瘤苗%基因療法%β-葡萄糖神經酰胺
수돌상세포%HBs-Ag기인%HepG2 22.1.5간암세포%류묘%기인요법%β-포도당신경선알
Dendritic cells (DC)%HBs-Ag gene%HepG2 22.1.5 hepatoma cells%Vaccine%Gene therapy%β-GC
目的探讨β-葡萄糖神经酰胺（β-GC）联合乙型肝炎表面抗原（HBsAg）基因修饰树突状细胞（dendritic cell, DC）瘤苗治疗肝癌的作用。方法以重组腺病毒为载体构建HBsAg-DC瘤苗。将C57BL/6J小鼠随机分为6组（A-F，6只/组），其中A、B、C组接种PBS液2次，D、E、F组接种HBsAg-DC瘤苗2次。皮下注入HepG222.1.5肝癌细胞当天始， B、E组接受β-GC（1.5μg）腹腔注射，C、F组接受β-GC（15μg）灌胃给药，A、D组为安慰剂对照，比较不同组间移植瘤生长情况。结果 B、C组移植瘤生长较之A组明显受抑（P＜0.05），E、F组移植瘤生长较之D组明显受抑（P＜0.05）。A-F组移植瘤大小（mm3）分别为364.2±3.06，236.5±8.96，251.0±5.76，75.0±5.9，35.3±4.46，38.5±5.47。经腹腔注射给药与灌胃给药相比在抗瘤作用方面差异无统计学意义。结论β-GC经腹腔或灌胃给药均具有提高HBsAg-DC瘤苗的免疫治疗作用，其协同抗肿瘤效应的机制可能通过激活NKT细胞。
目的探討β-葡萄糖神經酰胺（β-GC）聯閤乙型肝炎錶麵抗原（HBsAg）基因脩飾樹突狀細胞（dendritic cell, DC）瘤苗治療肝癌的作用。方法以重組腺病毒為載體構建HBsAg-DC瘤苗。將C57BL/6J小鼠隨機分為6組（A-F，6隻/組），其中A、B、C組接種PBS液2次，D、E、F組接種HBsAg-DC瘤苗2次。皮下註入HepG222.1.5肝癌細胞噹天始， B、E組接受β-GC（1.5μg）腹腔註射，C、F組接受β-GC（15μg）灌胃給藥，A、D組為安慰劑對照，比較不同組間移植瘤生長情況。結果 B、C組移植瘤生長較之A組明顯受抑（P＜0.05），E、F組移植瘤生長較之D組明顯受抑（P＜0.05）。A-F組移植瘤大小（mm3）分彆為364.2±3.06，236.5±8.96，251.0±5.76，75.0±5.9，35.3±4.46，38.5±5.47。經腹腔註射給藥與灌胃給藥相比在抗瘤作用方麵差異無統計學意義。結論β-GC經腹腔或灌胃給藥均具有提高HBsAg-DC瘤苗的免疫治療作用，其協同抗腫瘤效應的機製可能通過激活NKT細胞。
목적탐토β-포도당신경선알（β-GC）연합을형간염표면항원（HBsAg）기인수식수돌상세포（dendritic cell, DC）류묘치료간암적작용。방법이중조선병독위재체구건HBsAg-DC류묘。장C57BL/6J소서수궤분위6조（A-F，6지/조），기중A、B、C조접충PBS액2차，D、E、F조접충HBsAg-DC류묘2차。피하주입HepG222.1.5간암세포당천시， B、E조접수β-GC（1.5μg）복강주사，C、F조접수β-GC（15μg）관위급약，A、D조위안위제대조，비교불동조간이식류생장정황。결과 B、C조이식류생장교지A조명현수억（P＜0.05），E、F조이식류생장교지D조명현수억（P＜0.05）。A-F조이식류대소（mm3）분별위364.2±3.06，236.5±8.96，251.0±5.76，75.0±5.9，35.3±4.46，38.5±5.47。경복강주사급약여관위급약상비재항류작용방면차이무통계학의의。결론β-GC경복강혹관위급약균구유제고HBsAg-DC류묘적면역치료작용，기협동항종류효응적궤제가능통과격활NKT세포。
Objective To explore the efficacy ofβ-GC combined with HBsAg gene-modified DC vaccine on animal model with HCC using different immunization routes. Methods Recombinant adenovirus vector-mediated HBsAg gene-modified DC was used to construct HBsAg-DC which was infused into C57BL/6J mice bearing HBsAg-related HCC by subcutaneous injection. Mice in group A, B and C were vaccinated with PBS, group D, E and F were vaccinated with pAd-HBsAg-DC twice before HepG2 22.1.5 inoculation as described above. Starting at the day of inoculation, mice were treated with daily intra-peritoneal. (ip, 1.5μg per mouse)β-GC injection in group B and E or daily oralβ-GC doses(po, 15μg per mouse) in group C and F. Group A and D receiving vehicle (po) were set as control forβ-GC treatment.The effectiveness of the immune therapy on tumor growth was compared among different groups. Results Tumor size measured 36 days after inoculation was (364.2±3.06)mm3 in group A, (236.5±8.96)mm3 in group B, (251.0±5.76)mm3 in group C, (75.0±5.9)mm3 in group D, (35.3±4.46)mm3 in group E, and (38.5±5.47)mm3 in group F. The application ofβ-GC demonstrated anti-tumor activity by itself (group B and C), and also enhanced the tumor preventive effect of pAd-HBsAg-DC (group E and F). No difference in tumor growth was observed between ip and po application ofβ-GC. Conclusion β-GC may serve as an immune enhancer to augment the anti-tumor immunity triggered by HBsAg gene-modified DC vaccine. It's antitumor effect may be related to activation of NKT cells.
